In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Together Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TASE:TGTR - Analysts future estimates and past financials data (ILS Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	96	-3	11	13	N/A
3/31/2024	93	-3	12	14	N/A
12/31/2023	91	-4	14	15	N/A
9/30/2023	79	-9	9	10	N/A
6/30/2023	67	-14	4	5	N/A
3/31/2023	49	-24	-5	-4	N/A
12/31/2022	31	-34	-14	-14	N/A
9/30/2022	23	-29	-15	-14	N/A
6/30/2022	16	-23	-19	-19	N/A
3/31/2022	14	-19	-16	-15	N/A
12/31/2021	12	-14	-20	-19	N/A
9/30/2021	14	-14	-25	-20	N/A
6/30/2021	13	-2	-25	-10	N/A
3/31/2021	13	7	-28	-12	N/A
12/31/2020	11	7	-29	-10	N/A
9/30/2020	7	9	-27	-8	N/A
6/30/2020	4	-2	-26	-12	N/A
3/31/2020	1	-12	-27	-11	N/A
12/31/2019	N/A	-15	-23	-7	N/A
9/30/2019	N/A	-15	-27	-9	N/A
6/30/2019	N/A	-15	-31	-10	N/A
3/31/2019	N/A	-82	-25	-8	N/A
12/31/2018	N/A	-150	-19	-5	N/A
9/30/2018	N/A	-147	-11	-4	N/A
6/30/2018	N/A	-144	-4	-2	N/A
3/31/2018	N/A	-72	N/A	-1	N/A
12/31/2017	N/A	0	N/A	N/A	N/A
9/30/2017	-2	-1	N/A	-1	N/A
6/30/2017	-2	-1	N/A	-2	N/A
3/31/2017	-2	-2	N/A	-2	N/A
12/31/2016	N/A	-2	N/A	-3	N/A
9/30/2016	6	-1	N/A	-2	N/A
6/30/2016	8	-2	N/A	-2	N/A
3/31/2016	11	-1	N/A	-4	N/A
12/31/2015	N/A	-4	N/A	-4	N/A
9/30/2015	12	-2	N/A	-5	N/A
6/30/2015	11	-3	N/A	-5	N/A
3/31/2015	10	-5	N/A	-2	N/A
12/31/2014	8	-5	N/A	-3	N/A
9/30/2014	5	-6	N/A	-3	N/A
6/30/2014	3	-6	N/A	-3	N/A
3/31/2014	1	-4	N/A	-4	N/A
12/31/2013	1	-4	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if TGTR's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if TGTR's earnings are forecast to grow faster than the IL market

High Growth Earnings: Insufficient data to determine if TGTR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if TGTR's revenue is forecast to grow faster than the IL market.

High Growth Revenue: Insufficient data to determine if TGTR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TGTR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 09:39
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Together Pharma Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Together Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Market Cool On Together Pharma Ltd's (TLV:TGTR) Revenues

Together Pharma Ltd SHS to be Deleted from OTC Equity

Is Together Pharma (TLV:TGTR) A Risky Investment?

New major risk - Revenue and earnings growth

Investors Holding Back On Together Pharma Ltd (TLV:TGTR)

New major risk - Shareholder dilution

Together Pharma (TLV:TGTR) Is Achieving High Returns On Its Capital

Further Upside For Together Pharma Ltd (TLV:TGTR) Shares Could Introduce Price Risks After 49% Bounce

Full year 2023 earnings released: ₪0.49 loss per share (vs ₪4.15 loss in FY 2022)

New minor risk - Financial data availability

A Piece Of The Puzzle Missing From Together Pharma Ltd's (TLV:TGTR) Share Price

Returns At Together Pharma (TLV:TGTR) Are On The Way Up

Together Pharma (TLV:TGTR) Has A Somewhat Strained Balance Sheet

Together Pharma Ltd's (TLV:TGTR) 35% Jump Shows Its Popularity With Investors

Together Pharma Ltd's (TLV:TGTR) 35% Jump Shows Its Popularity With Investors

New minor risk - Share price stability

Less than half of directors are independent

First half 2022 earnings released: ₪0.19 loss per share (vs ₪0.082 loss in 1H 2021)

Is Together Pharma (TLV:TGTR) Using Debt Sensibly?

Less than half of directors are independent

Is Together Pharma (TLV:TGTR) Using Too Much Debt?

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Together Pharma (TLV:TGTR) Is Looking To Continue Growing Its Returns On Capital

Second quarter 2021 earnings released: ₪0.057 loss per share (vs ₪0.091 profit in 2Q 2020)

Is Together Pharma (TLV:TGTR) Using Too Much Debt?

Investor sentiment improved over the past week

Together Pharma (TLV:TGTR) Might Have The Makings Of A Multi-Bagger

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Here's Why Together Pharma (TLV:TGTR) Has A Meaningful Debt Burden

New 90-day low: ₪1.91

New 90-day low: ₪2.09

New 90-day low: ₪2.44

Can Together Pharma (TLV:TGTR) Continue To Grow Its Returns On Capital?

New 90-day high - ₪3.03